Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

Envestnet Portfolio Solutions Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 8.1% during the fourth quarter, according to its most recent Form 13F filing ...

UTHR stock opened at $322.94 on Friday. The company has a market capitalization of $14.50 billion, a PE ratio of 14.18, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics has a 12-month ...

With a solid Zacks Rank and top-tier Value and VGM Style Scores, UTHR should be on investors' short list. Should You Invest in United Therapeutics Corporation (UTHR)? Before you invest in United ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

UTHR sits at a Zacks Rank #3 (Hold), holds a Value Style Score of A, and has a VGM Score of B. Compared to the Medical - Drugs industry's P/E of 14.4X, shares of United Therapeutics are trading at ...

UTHR sits at a Zacks Rank #3 (Hold), holds a Value Style Score of A, and has a VGM Score of B. Compared to the Medical - Drugs industry's P/E of 14.4X, shares of United Therapeutics are trading at a ...